Cefotaxime
(Synonyms: 头孢噻肟酸,Cefotaxim; HR-756) 目录号 : GC60685
Cefotaxime是一种具有广谱抗菌活性的第三代头孢菌素类抗生素。它最常用于治疗革兰氏阳性菌或革兰氏阴性菌引起的传染病。
Cas No.:63527-52-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cefotaxime is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity. It is most commonly prescribed for the treatment of infectious diseases induced by Gram-positive or Gram-negative bacteria[1].
Cefotaxime (200, 400, 600, or 1000μg/mL; 24h) significantly promotes ROS generation in HT1080 cells[1]. Cefotaxime (0.02-2µg/ml, 5h) combined with Mecillinam could eliminate both cephalosporin-resistant bacteria harbouring CTX-M-15WT and mecillinam-resistant bacteria harbouring the mutant CTX-M-15N135D, thereby constraining resistance evolution of β-lactamase CTX-M-15[2].
Cefotaxime (200 or 400mg/kg/8h, 9 injections, subcutaneous injection) significantly increased bacterial clearance from the pneumonia model in leukopenic mice[3]. Cefotaxime (100mg/kg/4h, 24h, subcutaneous injections) combined with Amoxicillin-Clavulanate significantly reduces bacterial counts and achieves kidney sterilization in in a Murine Urinary Tract Infection Model[4].
References:
[1] Yamada M, Suzuki M, Noguchi T, et al. The antibiotic cefotaxime works as both an activator of Nrf2 and an inducer of HSP70 in mammalian cells. BPB reports. 2020;3(1):16-21.
[2] Rosenkilde CE, Munck C, Porse A, et al. Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase. Nature communications. 2019 Feb 6;10(1):618.
[3] Sauve C, Azoulay-Dupuis E, Moine P, et al. Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin-and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrobial agents and chemotherapy. 1996 Dec;40(12):2829-34.
[4] Rossi B, Soubirou JF, Chau F, et al. Cefotaxime and amoxicillin-clavulanate synergism against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of urinary tract infection. Antimicrobial Agents and Chemotherapy. 2016 Jan;60(1):424-30.
Cefotaxime是一种具有广谱抗菌活性的第三代头孢菌素类抗生素。它最常用于治疗革兰氏阳性菌或革兰氏阴性菌引起的传染病[1]。
Cefotaxime（200、400、600或1000μg/mL，24小时）显著促进HT1080细胞中的ROS生成[1]。Cefotaxime（0.02-2µg/ml，5h）与Mecillinam联合应用，可以同时消灭携带CTX-M-15WT的头孢菌素耐药菌和携带突变体CTX-M-15N135D的Mecillinam耐药菌，从而抑制β-内酰胺酶CTX-M-15的耐药性进化[2]。
Cefotaxime（200或400mg/kg/8小时，9次注射，皮下注射）显著增加白细胞减少小鼠的肺炎模型中的细菌清除率[3]。Cefotaxime（100mg/kg/4h，24h，皮下注射）与Amoxicillin-Clavulanate联合使用，在小鼠尿路感染模型中显著降低细菌数量并实现肾脏消毒[4]。
| Cell experiment [1]: | |
Cell lines | Human fibrosarcoma HT1080 cells |
Preparation Method | HT1080 cells were seeded on glass plates and treated with the indicated concentrations (200, 400, 600, or 1000μg/mL) of Cefotaxime for 24h. After stimulation, cells were treated with 10µM DCFH-DA for 30min at 37°C. After washing with PBS, the intracellular ROS generation was observed under laser confocal microscope. |
Reaction Conditions | 200, 400, 600, or 1000μg/mL; 24h |
Applications | Cefotaxime significantly promotes ROS generation in HT1080 cells. |
| Animal experiment [2]: | |
Animal models | Pneumonia model in leukopenic mice |
Preparation Method | Amoxicillin (AMO) and Cefotaxime (CTX) were administered at 8-h intervals with a total of nine injections, and Ceftriaxone (CRO) was given at 12-h intervals with a total of six injections. The dose of each antibiotic varied with the infective strain. Mice infected with strain P40422 were treated with AMO or CTX at 200 or 400mg/kg or with CRO at 100mg/kg. Mice infected with P40984 were treated with AMO at 200 or 400mg/kg, CTX at 400mg/kg, or CRO at 100 or 200mg/kg. Each dose was administered subcutaneously (s.c.) in 0.5ml of sterile water. Control animals received the same volume of isotonic saline. |
Dosage form | 200 or 400mg/kg/8h, 9 injections, subcutaneous injection |
Applications | Cefotaxime significantly increased bacterial clearance from the pneumonia model in leukopenic mice. |
References: | |
| Cas No. | 63527-52-6 | SDF | |
| 别名 | 头孢噻肟酸,Cefotaxim; HR-756 | ||
| Canonical SMILES | O=C(C(N12)=C(COC(C)=O)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O | ||
| 分子式 | C16H17N5O7S2 | 分子量 | 455.47 |
| 溶解度 | DMSO: 250 mg/mL (548.88 mM) | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1955 mL | 10.9777 mL | 21.9553 mL |
| 5 mM | 0.4391 mL | 2.1955 mL | 4.3911 mL |
| 10 mM | 0.2196 mL | 1.0978 mL | 2.1955 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet